BioVaxys Update: Extended Financing Opportunity Announced
BioVaxys Announces Extended Closing Date for Financing
BioVaxys Technology Corp. (CSE: BIOV) has recently extended the closing date of its brokered private placement financing, presenting an opportune moment for investors. This offering includes a minimum of 5,714,285 units, priced at $0.35 per unit, striving for a total gross amount of approximately $2,000,000 to $3,000,000.
Structure of the Offering
The offering comprises units that contain one post-consolidation common share along with one warrant. Each warrant permits the purchase of an additional share at a post-consolidation rate of $0.50, valid for 36 months following the offering's closing.
Engagement of Agents for Support
BioVaxys has enlisted the expertise of brokers including Enclave Capital LLC and D12 Capital Markets Inc. as agents for this offering. After successful closure, Enclave will receive an 8% fee on total proceeds from its investors, alongside a fixed cash fee of $10,000. D12’s commission will follow a similar approach, compensating them for their introductions.
Utilization of Funds Raised
The proceeds from this financing are anticipated to be utilized primarily for research and development efforts, while also supporting general corporate purposes and working capital needs. The target date for closing this offering aligns with a 45-day timeframe post-announcement.
Offering Compliance and Sale Conditions
Under National Instrument 45-106, the units will be offered for sale in provinces and territories of Canada except for Quebec. Investors can purchase these units under the listed issuer financing exemption, with no resale restrictions for sold securities in accordance with Canadian securities laws.
Consolidation of Common Shares
In conjunction with this financing, BioVaxys plans to undergo a consolidation of its common shares. Following this consolidation, the company anticipates having around 29,342,520 common shares issued and outstanding, reflecting a significant reduction in the number of shares per the consolidation ratio of 10 to 1.
Implications of the Consolidation
This consolidation will proportionately adjust the exercise prices of any convertible securities BioVaxys has. Importantly, the company ensures that no fractional common shares will be distributed, maintaining a clear structure for its common shares post-consolidation.
Future Communication from BioVaxys
Further announcements regarding the effective date of the consolidation and new identifiers for shares will be made public, along with any related information necessary for stakeholders.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. is dedicated to innovative solutions within the biopharmaceuticals landscape. Its focus is on developing immunotherapies leveraging the DPX™ immune-educating technology platform. Such innovations target a range of medical needs from cancer to infectious diseases. The company is actively progressing with products such as maveropepimut-S (MVP-S), which targets advanced lymphomas amongst other cancers.
Conclusion and Contact Information
In light of the recent developments, BioVaxys continues to demonstrate its commitment to enhancing healthcare through innovative therapies. Stakeholders are encouraged to stay informed through future press releases and the corporate website.
Contact Details:
James Passin, Chief Executive Officer
Phone: +1 740 358 0555
Frequently Asked Questions
What is the significance of the extended closing date?
The extended closing date allows investors more time to participate in the financing, enhancing the potential for raising necessary funds for the company's initiatives.
What is included in each unit offered?
Each unit comprises one common share and one warrant, allowing the holder to buy additional shares at a fixed price.
How does the consolidation affect current shareholders?
The consolidation reduces the number of existing shares while maintaining shareholder value through proportional adjustments of securities.
What will BioVaxys do with the funds raised?
The funds will primarily be allocated for research and development, as well as general corporate purposes to drive future growth.
Where can I find more information about BioVaxys?
More information is available on BioVaxys's official website, where news and updates are regularly posted for investors and stakeholders.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
